myrcludex-B: Clinical Trials

8 trials of myrcludex-B, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 5 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 5
Phase 14Completed 4
Phase 31Completed 1

Follow myrcludex-B: new trials by email Literature Review of myrcludex-B trials Research Report on myrcludex-B

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
Bulevirtide - Hepatic Impairment, Healthy
Phase 1CompletedGilead Sciences742023-03-152026-01-26
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
Bulevirtide (BLV) - Chronic Hepatitis D Infection
Phase 1CompletedGilead Sciences412023-03-152025-09-18
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa) - Chronic Hepatitis Delta
Phase 2CompletedGilead Sciences1752019-05-312024-10-08
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
Bulevirtide - Chronic Hepatitis Delta
Phase 3CompletedGilead Sciences1502019-04-172025-08-22
Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent
Myrcludex B, PEG IFN alfa-2a, Tenofovir - Chronic Viral Hepatitis B With Delta-agent
Phase 2CompletedHepatera Ltd.902016-04-012021-04-30
A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D
Myrcludex B, Myrcludex-B, Tenofovir - Chronic Hepatitis D Infection With Hepatitis B
Phase 2CompletedHepatera Ltd.1202016-02-162021-05-10
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
PEG IFN alfa-2a, Myrcludex B - Chronic Hepatitis D Infection
Phase 1 / Phase 2CompletedHepatera Ltd.242014-02-132018-04-13
Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
Entecavir, Myrcludex B - Chronic Hepatitis B
Phase 1 / Phase 2CompletedHepatera Ltd.482012-11-142018-09-19

Conditions studied

Hepatitis D, Chronic (2)  ·  Hepatitis B, Chronic (1)  ·  Hepatitis D (1)

Sponsors

Gilead Sciences (4)  ·  Hepatera Ltd. (4)

Countries

Russia (5)  ·  United States (3)  ·  Germany (2)  ·  France (1)  ·  Italy (1)  ·  Moldova (1)  ·  Romania (1)  ·  Sweden (1)

Top investigators

Pavel Bogomolov, PhD (3)  ·  Heiner Wedemeyer, MD,PhD (1)

Results publications

PMID 38340811, PMID 39648559, PMID 37120031, PMID 36113537, PMID 38842520, PMID 39009085, PMID 39853842, PMID 41405233, PMID 41966308

NIH funding

2019 (2)